Pallas Capital Advisors LLC Invests $1.21 Million in United Therapeutics Corporation $UTHR

Pallas Capital Advisors LLC purchased a new stake in United Therapeutics Corporation (NASDAQ:UTHR) during the 2nd quarter, Holdings Channel.com reports. The fund purchased 2,227 shares of the biotechnology company’s stock, valued at approximately $1,207,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Avoro Capital Advisors LLC lifted its position in United Therapeutics by 17.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock worth $1,269,803,000 after acquiring an additional 383,838 shares during the period. Wellington Management Group LLP increased its holdings in shares of United Therapeutics by 74.5% in the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock valued at $1,189,617,000 after purchasing an additional 1,042,711 shares during the period. AQR Capital Management LLC raised its stake in shares of United Therapeutics by 29.9% during the fourth quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company’s stock worth $624,508,000 after purchasing an additional 295,221 shares during the last quarter. Janus Henderson Group PLC grew its position in United Therapeutics by 8.9% in the 1st quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock valued at $514,016,000 after buying an additional 70,829 shares during the last quarter. Finally, Norges Bank acquired a new position in United Therapeutics in the 4th quarter valued at $293,418,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Stock Up 1.9%

NASDAQ:UTHR opened at $518.27 on Wednesday. United Therapeutics Corporation has a fifty-two week low of $302.19 and a fifty-two week high of $609.35. The stock has a market cap of $22.23 billion, a PE ratio of 18.54, a price-to-earnings-growth ratio of 1.69 and a beta of 0.59. The firm’s fifty day simple moving average is $534.53 and its 200-day simple moving average is $536.74.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, beating the consensus estimate of $6.86 by $0.41. The firm had revenue of $783.30 million during the quarter, compared to analysts’ expectations of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The business’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same quarter last year, the business earned $6.41 earnings per share. Equities analysts anticipate that United Therapeutics Corporation will post 26.33 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. Royal Bank Of Canada reduced their target price on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. Weiss Ratings upgraded shares of United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, August 13th. Morgan Stanley set a $515.00 price target on shares of United Therapeutics in a report on Thursday, August 6th. Bank of America lowered their price objective on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. Finally, Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $575.00 to $735.00 in a research note on Thursday, May 7th. Eleven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $646.00.

Insider Transactions at United Therapeutics

In other news, CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $564.11, for a total transaction of $5,641,100.00. Following the completion of the sale, the chief financial officer directly owned 18,876 shares in the company, valued at approximately $10,648,140.36. This trade represents a 34.63% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Martine A. Rothblatt sold 9,500 shares of the business’s stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $547.61, for a total value of $5,202,295.00. Following the sale, the chief executive officer directly owned 40,513 shares in the company, valued at $22,185,323.93. This trade represents a 19.00% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 452,575 shares of company stock valued at $245,684,184. 8.60% of the stock is currently owned by corporate insiders.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.